-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $48

Benzinga·07/22/2026 18:50:22
Listen to the news
Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $54 to $48.